Positive percentage fraction of PCP4/PEP19 relative to that of aromatase was 69.2% in ER+ breast cancers, but only 22.5% in ER- cancers (p=0.011) (Table 2). This evidence concerns the gene CYP19A1 and breast carcinoma.